Trial Profile
A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 1248 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme
- 18 Aug 2020 Results published in the Cancer
- 15 Oct 2019 Status changed from completed to discontinued.
- 14 Nov 2018 Status changed from active, no longer recruiting to completed.